Medical Advocates
Lamivudine (Epivir)
 
HBV Efficacy Journal Citations

General Reports
 Combination Therapy
Drug Comparison Studies
Cirrhosis
 Extrahepatic Disease
 Fulminant Hepatitis B
 HBV/Hepatocellular Carcinoma
 Liver Transplants


 
Lamivudine HBV Main Page Main New/Newsworthy  Home Page      

Last Update:  July 06, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader .

General Reports
 
 
.FULL-TEXT ARTCLE
 Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand.
 Khamduang W, Gaudy-Graffin C,  et al
PLoS One. 2012;7(7):e42184.
Paper

 Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.
Kennedy PT, Phillips N, et al  
Liver Int. 2008 May;28(5):699-704.
 Abstract

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive
cancer patients undergoing cytotoxic chemotherapy.
Cil T, Altintas A, Pasa S, Bayan K, et al 
Leuk Lymphoma. 2008 May;49(5):939-47.
 Abstract
 
Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients:
systematic review and meta-analysis.
Katz LH, Fraser A, Gafter-Gvili A, et al
J Viral Hepat. 2008 Feb;15(2):89-102.
 Abstract
 
Lamivudine therapy in patients with severe acute hepatitis B
Roznovský L, Orságová I, Kloudová A, Mrázek J.
Klin Mikrobiol Infekc Lek. 2007 Apr;13(2):59-65
Abstract
 
Lamivudine for treatment of spontaneous exacerbation and reactivation after immunosuppressive
therapy in patients with hepatitis B virus infection.
Inoue T, Fuke H, Yamamoto N, et al
Hepatogastroenterology. 2007 Apr-May;54(75):889-91.
 Abstract
 
Clinical Outcomes of Lamivudine Therapy in HBeAg Positive Chronic Hepatitis B with Minimally
Elevated ALT.
Han DH, Park NH, Shin JW, et al
Korean J Hepatol. 2007 Jun;13(2):146-56.
 Abstract
 
Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection.
Kawaoka T, Suzuki F, Akuta N, et al
J Gastroenterol. 2007 May;42(5):395-401.
 Abstract
 
Response to long-term lamivudine treatment in patients infected with hepatitis B virus
genotypes A, B, and C.
Kobayashi M, Suzuki F, Akuta N, et al 
J Med Virol. 2006 Oct;78(10):1276-83.
 Abstract
 
Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation.
Wang SS, Chou NK, Chi NH, et al 
Transplant Proc. 2006 Sep;38(7):2138-40
 Abstract
 
Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.
Hache C, Villeneuve JP.
Expert Opin Pharmacother. 2006 Sep;7(13):1835-43.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Comparison of Clinical Outcome Between Patients Continuing and Discontinuing Lamivudine
Therapy in Acute Exacerbation After Viral breakthrough During Lamivudine Therapy in Chronic
 Hepatitis B.
Eun JR.
Korean J Hepatol. 2006 Jun;12(2):184-90.
 Abstract
 
Successful lamivudine therapy for chronic hepatitis B in the family
Nozic D.
Vojnosanit Pregl. 2006 May;63(5):504-7.
 Abstract
 
Prolonged lamivudine treatment in patients with chronic active anti-HBe-positive hepatitis.
Scotto G, Palumbo E, Fazio V 
Am J Ther. 2006 May-Jun;13(3):218-22.
 Abstract
 
Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-
breakthrough and long-term clinical outcome.
Manolakopoulos S, Bethanis S, Elefsiniotis J, et al  
Aliment Pharmacol Ther. 2006 Mar 15;23(6):787-95.
 Abstract
 
Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg
after lamivudine therapy.
Byun KS, Kwon OS, Kim JH  
 J Gastroenterol Hepatol. 2005 Dec;20(12):1838-42.
 Abstract
 
Treatment response to lamivudine in chronic hepatitis B patients.
Manas Garcia MD, Domper Bardaji F, et al 
An Med Interna. 2005 Oct;22(10):485-8.
 Abstract
 
Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis
B infection.
Gan SI, Devlin S, Scott-Douglas NW, Burak KW.
Can J Gastroenterol. 2005 Sep;19(10):625-9.
Abstract

FULL-TEXT ARTICLE
 Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg
and HBV DNA according to pretreatment ALT level.
Kurihara T, Imazeki F, Yokosuka O, et al
World J Gastroenterol. 2005 Jun 14;11(22):3346-50.
 Paper
 
  Long term hepatitis B therapy with lamivudine: a major step forward but can we do even better?
Perrillo RP .
J Hepatol. 2005 Jun;42(6):953-5.
Abstract
 
  Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.
Tsubota A, Arase Y, Suzuki Y, et al 
J Gastroenterol Hepatol. 2005 Mar;20(3):426-32.
 Abstract|
 
  Lamivudine for patients with chronic hepatitis B and advanced liver disease.
Liaw YF, Sung JJ, Chow WC,
N Engl J Med. 2004 Oct 7;351(15):1521-31.
 Abstract
 
  Virological and biochemical relapse according to YMDD motif mutant type during long-term
lamivudine monotherapy.
Akuta N, Suzuki F, Kobayashi M, et al  
J Med Virol. 2003 Dec;71(4):504-510.
 Abstract
 
  The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5
years observation.
Ohkoshi S, Ogata N, Ichida T.
Hepatol Res. 2003 Sep;27(1):13-17.
 Abstract
 
  Dramatic Reduction of the alpha-Fetoprotein Level After Lamivudine Treatment of Patients
with Chronic Hepatitis B Virus Infection and Cirrhosis.
Yao FY. 
J Clin Gastroenterol 2003 May-Jun;36(5):440-2
 Abstract
 
  Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Dienstag JL, Cianciara J, Karayalcin S, et al.
Hepatology 2003 Apr;37(4):748-755
 Abstract
 
  The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of
chronic hepatitis B.
Chien RN, Lin CH, Liaw YF. 
J Hepatol 2003 Mar;38(3):322-7
 Abstract
 
 
Histological outcome during long-term lamivudine therapy.
Dienstag JL, Goldin RD, Heathcote EJ, et al.
 Gastroenterology 2003 Jan;124(1):105-117
 Abstract
 
Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in
chronic hepatitis B infection: emergence of YMDD motif mutant and risk of
breakthrough hepatitis - an open-cohort study.
 Akuta N, Tsubota A, Suzuki F, et al.
 J Hepatol 2003 Jan;38(1):91-7
  Abstract
 
The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B
with jaundice.
Chan HL, Tsang SW, Hui Y, et al.
 Viral Hepat 2002 Nov;9(6):424-8
 Abstract
 
Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with
acute exacerbation.
 Lee CM, Ong GY, Lu SN
 J Hepatol 2002 Nov;37(5):669-74|
 Abstract
 
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver
transplantation for chronic hepatitis B.
Fontana RJ, Keeffe EB, Carey W, et al.  
Liver Transpl 2002 May;8(5):433-9
 Abstract
 
Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.
Rizzetto M
J Med Virol 2002 Apr;66(4):435-51
 Abstract
 
Lamivudine treatment failure in preventing fatal outcome of de novo severe acute
hepatitis B in  patients with haematological diseases.
Petrelli E, Balducci M, Pieretti C,  et al.
J Hepatol 2001 Dec;35(6):823-826
 Abstract
 
Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough
hepatitis evaluated by serial viral loads and full-length viral sequences.
Liu CJ, Chen PJ, Lai MY,  Kao JH, Chen DS.
Hepatology 2001 Sep;34(3):583-589
 Abstract
Combination Therapy
 
Lamivudine/HBV Vaccine
 
  Combination therapy with lamivudine and HB vaccine on chronic hepatitis B.
Ishikawa T, Kakumu S.  
Hepatol Res. 2007 Jul;37(s1):S62-6.
 Abstract

Lamivudine/Interferon

 
 
Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic
hepatitis B patients: a pilot study.
Niro GA, Fontana R, Gioffreda D, et al
Dig Liver Dis. 2007 Sep;39(9):857-63.
 Abstract

Lamivudine does not increase the efficacy of interferon in the treatment of mutant type
chronic viral heptitis B.
Yang SS, Hsu CT, Hu JT, et al.
World J Gastroenterol 2002 Oct;8(5):868-71
 Abstract

Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon
combination and alpha-interferon alone.
Dikici B, Bosnak M, Bosnak V, et al.
Pediatr Int 2002 Oct;44(5):517-21
 Abstract

Lamivudine/IL--2

  Clinical and immunological efficacy of intradermal vaccine plus lamivudine with  or without
interleukin-2 in patients with chronic hepatitis B. 
Dahmen A, Herzog-Hauff S,  Bocher WO, et al.
J Med Virol 2002 Apr;66(4):452-60
 Abstract

Lamivudine/Tenofovir

 
Rapid Improvement of Liver Function in a Patient with HIV and Hepatitis B Coinfection Treated
with Lamivudine and Tenofovir.
 Lehmann C, Wyen C, Fatkenheuer G. et al 
Infection. 2006 Aug;34(4):234-5.
 Abstract
 
Wild type and YMDD variant of hepatitis B virus: No difference in viral kinetics on
lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
de Vries-Sluijs TE, van der Eijk AA, Hansen BE, et al
J Clin Virol. 2006 Jan 14;
Abstract

Ninety-Six-Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in
Patients Coinfected with HIV-1 and Wild-Type Hepatitis B Virus.
Bani-Sadr F, Palmer P, Scieux C, Molina JM.   
 Clin Infect Dis. 2004 Oct 1;39(7):1062-4.
Abstract
 
Lamivudine/Peginterferon alfa-2b
 
  Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with
lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
Vassiliadis T, Tziomalos K, Patsiaoura K, et al 
J Gastroenterol Hepatol. 2007 Oct;22(10):1582-8.
 Abstract
Drug Comparison Studies
 
  FULL-TEXT ARTICLE
 A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
 Chen WC, Cheng JS, Chiang PH, et al
PLoS One. 2015 Jun 29;10(6):e0131545.
 Paper

Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive
chronic hepatitis B.
Arase Y, Ikeda K, Suzuki F, et al 
J Med Virol. 2007 Sep;79(9):1286-92.
 Abstract
Cirrhosis
 
 
The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
Kilic ZM, Kuran S, Akdogan M, et al; 
Adv Ther. 2008 Apr 2.
 Abstract
 
Lamivudine treatment-related morphological changes of esophageal varices in patients with liver
cirrhosis.
Koga H, Ide T, Oho K, Kuwahara R, et al
Hepatol Res. 2007 Jul;37(7):503-9.
 Abstract
 
FULL TEXT ARTICLE
 Effects of lamivudine on serum albumin levels correlate with pretreatment
HBV-DNA levels in cirrhotic patients.
Nakamuta M, Kotoh K, Enjoji M, et al
Comp Hepatol. 2007 May 1;6:3
 Paper
 
Sustained clinical improvement of a patient with decompensated hepatitis B virus-related
cirrhosis after treatment with Lamivudine monotherapy.
Nagasaki F, Ueno Y, Yamamoto T, et al
 Tohoku J Exp Med. 2006 Sep;210(1):29-36.
 Abstract
 
Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.
Hache C, Villeneuve JP.
Expert Opin Pharmacother. 2006 Sep;7(13):1835-43.
Abstract
 
Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis
B patients.
Nikolaidis NL, Giouleme OI, Tziomalos KA, et al
 J Gastroenterol Hepatol. 2005 Nov;20(11):1721-5.
Abstract
 
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B
virus-related decompensated liver cirrhosis.
Tseng PL, Lu SN, Tung HD, Wang JH, et al 
J Viral Hepat. 2005 Jul;12(4):386-92.
 Abstract

A United States compassionate use study of lamivudine treatment in nontransplantation
candidates with decompensated hepatitis B virus-related cirrhosis.
Hann HW, Fontana RJ, Wright T, etc.
 Liver Transpl 2003 Jan;9(1):49-56
 Abstract
 

Effects of lamivudine on cirrhotic patients following chronic hepatitis B
Wang HN, Hu YY, Hong JH, et al
Zhonghua Gan Zang Bing Za Zhi 2002 Oct 20;10(5):382
 Abstract
Extrahepatic Disease
 

Aplastic Anemia

  Remission of severe aplastic anemia associated with hepatitis B virus infection after viral
clearance: potential role of lamivudine.
Bozkaya H, Yurdaydin C, Toruner M, et al. 
Dig Dis Sci 2002 Aug;47(8):1782-5
 Abstract
Kidney Disease
 
  Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous
glomerulopathy after lamivudine monotherapy.
Chuang TW, Hung CH, Huang SC, Lee CM.  
J Formos Med Assoc. 2007 Oct;106(10):869-73
 Abstract
Fulminant Hepatitis B
 
  Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B,
a multicenter experience.
Tillmann HL, Hadem J, Leifeld L, et al  
J Viral Hepat. 2006 Apr;13(4):256-63.
 Abstract
HBV/Hepatocellular Carcinoma
 
 
Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in
patients with active replication of hepatitis B virus.
Kubo S, Tanaka H, Takemura S
Hepatol Res. 2007 Feb;37(2):94-100.
Abstract

Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma
coexisting with chronic hepatitis B infection.
Shuqun C, Mengchao W, Han C, et al; 
Hepatogastroenterology. 2006 Mar-Apr;53(68):249-52.
 Abstract
Liver Transplants
 
  Lamivudine monoprophylaxis for liver transplant recipients with non-replicating
hepatitis B virus infection.
Yoshida H, Kato T, Levi DM, et al 
Clin Transplant. 2007 Mar-Apr;21(2):166-71
 Abstract

Lamivudine HBV Main Page Main New/Newsworthy  Home Page      

Lamivudine HBV Efficacy Data
Journal Papers, Abstracts, and Commentaries